Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314145 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX
A Phase 3 study of Japanese Encephalitis, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 820
- Enrollment target
- 10
- Study locations
NCT00314145: Completed Phase 3 study of Japanese Encephalitis, sponsored by Sanofi.
NCT00314145 is a Phase 3 study of Japanese Encephalitis that has completed, run by Sanofi. The registered enrollment target is 820 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00314145, a Phase 3 study of Japanese Encephalitis, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 820 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVaxTM-JE and JE-VAX to the respective homologous virus strain after completion of vaccination course.
Primary Outcome
Antibodies to Japanese encephalitis (JE) were measured by 50% plaque reduction neutralization test (PRNT50). Seroconversion was defined as a titer of ≥ 1:10.
Conditions Studied
Interventions
- BIOLOGICAL ChimeriVax™-JE
- BIOLOGICAL JE-VAX®
Study Locations (10)
Other
- - Adelaide
- - Melbourne
- - New South Wales
- - Queensland
- - Victoria
Illinois
- - Chicago
Kansas
- - Shawnee Mission
Montana
- - Missoula
Texas
- - Dallas
Washington
- - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 820 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
What the finished NCT00314145 record still lists
NCT00314145 is an interventional study that assigns participants to a tested intervention. The registered 820 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 1 condition, with Japanese Encephalitis appearing as the primary indexed condition, and to 2 interventions - of which ChimeriVax™-JE is the first listed.
NCT00314145 lists 10 locations in 6 states (Other, Illinois, Kansas).
Frequently Asked Questions
What is clinical trial NCT00314145 about?
NCT00314145 is a clinical study titled "A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX". The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVaxTM-JE and JE-VAX to the respective homologous virus strain after completion of vaccination course.
What is the current status of trial NCT00314145?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 820 participants. The study started on 2005-11. Estimated completion is 2006-11.
What conditions does trial NCT00314145 study?
This clinical trial studies the following conditions: Japanese Encephalitis.
What interventions are being tested in trial NCT00314145?
The interventions under investigation include: ChimeriVax™-JE (BIOLOGICAL), JE-VAX® (BIOLOGICAL).
Who is sponsoring clinical trial NCT00314145?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00314145 being conducted?
This trial has 10 study locations across Illinois, Kansas, Montana, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Japanese Encephalitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00314145's enrollment target sits among peer trials
820 404th of 2000 higher than 1,596 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
- NCT04613440 · 820 participants · NA
FaCT Trial (Facilitated Cascade Testing Trial)
- NCT04910269 · 820 participants · Phase 3
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
- NCT05679349 · 822 participants · NA
Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia